Saudi Food and Drug Authority approves registration of Pfizer coronavirus vaccine


JEDDAH: The Saudi Food and Drug Authority (SFDA) announced on Thursday that it has approved the Pfizer/BioNTech COVID-19 vaccine for use in the Kingdom.
The approval is based on a review of data provided by US pharmaceutical giant Pfizer and German partner BioNTech on November 24 and confirmation that it meets the authority’s requirements in regard to efficacy, safety, stability, and the manufacturer’s commitment to applying the principles of good manufacturing practice in accordance with international pharmaceutical standards.
In a previous comment, Ministry of Health spokesman Dr. Mohammed Al-Abd Al-Aly stated that no vaccine would be approved without going through the proper evaluation, as the health and safety of the Kingdom’s residents is the ministry’s topmost priority.
No date has yet been confirmed for the arrival of the vaccine in the Kingdom. The vaccine will go through a series of tests before it is cleared for use by the public.
Commenting on the government’s approval, BioNTech CEO Ugur Sahin said that registration for local use shows that the region is taking a proactive stance in bringing an end to the pandemic.
“From the beginning, our goal has been to develop a vaccine that would generate rapid and potent protection against COVID-19 with a benign tolerability profile across all ages,” Sahin said.
“Based on the data seen so far, we believe we have successfully accomplished this. The virus has no borders, so we are working to bring the vaccine to as many people globally as possible, as quickly as possible.”

Follow on Twitter and Facebook to join the conversation

Leave a Reply

Your email address will not be published.